More intelligence articles

Staying ahead in the era of precision medicine

A call to action for healthcare communicators

Alzheimer’s: the search for a cure

Will Biogen’s aducanumab re-energise the hunt for pharma’s white whale?

20 for 2020 – Five pharma leaders to watch in 2020

Five individuals we think will have a key role to play in the sector in 2020 and beyond

Mapping the patient journey and minding the gap

Seven steps to closing the gap between rhetoric and reality in patient-centricity

Putting commercial intelligence at the heart of strategy

Keys to gaining a competitive advantage and achieving success

Shanks v Unilever? Or David v Goliath?

Could inventive employees be in line for a big pay-out?

Boosting innovation in healthcare and scientific communications

It’s time for communications to be brave and bring the outside in

Case-study for thalassaemia: Dimitri Azzopardi

An in-depth look at beta thalassaemia for Rare Disease Day

Assessing the value of interim analyses in clinical trials

Why its important and when its needed

Can protein degraders unlock ‘undruggable’ drug targets?

Exploring a new and exciting area of small-molecule drug discovery

BRIC markets

Why these countries offer an opportunity for pharma despite a slowdown

Novo Nordisk awakens its ‘Sleeping Beauty’

Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott

20 for 2020 – Five pharma companies to watch

As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020

The roaring ‘20s and Generation Z

How a new generation will shape pharma comms this decade

It started with a miss

Is pharma finally heading for launch excellence?